Coherus and STORM Therapeutics Partner to Evaluate STC-15 with LOQTORZI in Clinical Trial
Coherus BioSciences, Inc. announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI…
Read More...
Read More...
